The PedsQL as a Pediatric Patient-Reported Outcome

Reliability and Validity of the PedsQL Measurement Model in 25,000 Children

by James W. Varni, Tasha M. Burwinkle, Michael Seid

Download Free Electronic Document

FormatFile SizeNotes
PDF file 1.7 MB

Use Adobe Acrobat Reader version 10 or higher for the best experience.

The PedsQL™ Measurement Model was designed as a modular approach to measuring pediatric health-related quality of life, and developed to integrate the relative merits of generic and disease-specific approaches. The PedsQL™ 4.0 Generic Core Scales have been translated into over 60 languages, with published data on over 25,000 children and adolescents in more than 75 peer-reviewed journals since 2001 for healthy children and numerous pediatric chronic health conditions. The PedsQL™ Disease and Condition-Specific Modules were designed to measure health-related quality-of-life dimensions specifically tailored for pediatric chronic health conditions, and include the PedsQL™ Asthma, Arthritis/Rheumatology, Cancer, Diabetes, Cardiac and Cerebral Palsy Modules, as well as the generic PedsQL™ Multidimensional Fatigue Scale, Pediatric Pain Questionnaire™, Family Impact Module and Healthcare Satisfaction Module. The PedsQL™ has demonstrated reliability, validity, sensitivity and responsiveness for child self report for ages 5-18 years and parent proxy report for ages 2-18 years. The PedsQL™ has been shown to be related to other key constructs in pediatric healthcare such as access to needed care, healthcare barriers and quality of primary care. Future advances in the PedsQL™ Measurement Model include web-based electronic administration (ePedsQL™), integration into the electronic medical record, further efficacy and effectiveness outcome trials, including PedsQL™ ResourceConnectSM and PedsQL™ TIPSSM, the development of the generic PedsQL™ Infant Scales for ages birth to 24 months and disease and condition-specific modules for other pediatric chronic health conditions.

Reprinted with permission from Expert Review of Pharmacoeconomics & Outcomes Research, Vol. 5, No. 6, December 2005, pp. 705-719. Copyright © 2005 Future Drugs Ltd.

Originally published in: Expert Review of Pharmacoeconomics & Outcomes Research, Vol. 5. No. 6. December 2005, pp. 705-719.

This report is part of the RAND Corporation reprint series. The Reprint was a product of the RAND Corporation from 1992 to 2011 that represented previously published journal articles, book chapters, and reports with the permission of the publisher. RAND reprints were formally reviewed in accordance with the publisher's editorial policy and compliant with RAND's rigorous quality assurance standards for quality and objectivity. For select current RAND journal articles, see External Publications.

Permission is given to duplicate this electronic document for personal use only, as long as it is unaltered and complete. Copies may not be duplicated for commercial purposes. Unauthorized posting of RAND PDFs to a non-RAND Web site is prohibited. RAND PDFs are protected under copyright law. For information on reprint and linking permissions, please visit the RAND Permissions page.

The RAND Corporation is a nonprofit institution that helps improve policy and decisionmaking through research and analysis. RAND's publications do not necessarily reflect the opinions of its research clients and sponsors.